Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2026 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.570-2.770 for the period, compared to the consensus estimate of 2.710. The company issued revenue guidance of $16.4 billion-$16.8 billion, compared to the consensus revenue estimate of $17.0 billion.

Teva Pharmaceutical Industries Trading Down 1.6%

Shares of Teva Pharmaceutical Industries stock traded down $0.52 on Wednesday, reaching $32.01. The company had a trading volume of 4,008,276 shares, compared to its average volume of 9,802,959. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The firm has a market cap of $36.71 billion, a PE ratio of 52.90, a PEG ratio of 1.83 and a beta of 0.66. The firm’s 50 day moving average price is $29.94 and its two-hundred day moving average price is $22.89. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $33.42.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.During the same quarter in the previous year, the business earned $0.71 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on TEVA. Barclays started coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target on the stock. Scotiabank began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price on the stock. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Sunday, January 18th. Finally, Bank of America lifted their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $33.67.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 622,060 shares of company stock valued at $17,076,965. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after acquiring an additional 6,878,304 shares during the period. Polar Capital Holdings Plc purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $80,983,000. Alyeska Investment Group L.P. boosted its stake in Teva Pharmaceutical Industries by 145.9% during the 3rd quarter. Alyeska Investment Group L.P. now owns 5,976,035 shares of the company’s stock worth $120,716,000 after purchasing an additional 3,545,577 shares during the period. Viking Global Investors LP grew its position in Teva Pharmaceutical Industries by 15.4% during the 2nd quarter. Viking Global Investors LP now owns 11,681,333 shares of the company’s stock worth $195,779,000 after purchasing an additional 1,555,855 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Teva Pharmaceutical Industries by 19.6% in the second quarter. Bank of America Corp DE now owns 9,004,963 shares of the company’s stock valued at $150,923,000 after purchasing an additional 1,473,740 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.